0001144204-18-000675.txt : 20180103 0001144204-18-000675.hdr.sgml : 20180103 20180103213631 ACCESSION NUMBER: 0001144204-18-000675 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180101 FILED AS OF DATE: 20180103 DATE AS OF CHANGE: 20180103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: COHEN RAYMOND W CENTRAL INDEX KEY: 0001258288 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 18508313 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 tv482654_4.xml OWNERSHIP DOCUMENT X0306 4 2018-01-01 0 0000834365 BIOLIFE SOLUTIONS INC BLFS 0001258288 COHEN RAYMOND W C/O BIOLIFE SOLUTIONS, INC. 3303 MONTE VILLA PARKWAY, SUITE 310 BOTHELL WA 98021 1 0 0 0 Common Stock 2018-01-01 4 A 0 15000 A 62531 D Common Stock 2018-01-03 4 A 0 3125 A 65656 D The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. Since the date of the reporting person's last ownership report, he transferred 10,537 shares of the issuer's common stock and options to purchase 21,425 shares of the issuer's common stock to his ex-wife pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-wife. The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $18,750 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter. /s/ Raymond W. Cohen 2018-01-03